Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ludwig Enterprises Inc (OP: LUDG )

0.1240 -0.0075 (-5.70%)
Streaming Delayed Price Updated: 11:38 AM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,387
Open 0.1350
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1315
Today's Range 0.1240 - 0.1350
52wk Range 0.0710 - 0.4300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ludwig Announces Substantial Corporate Initiatives
Via ACCESSWIRE
Ludwig Enterprises Files Provisional Patent on mRNA Genetic Screening Signals in Breast, Colon and Bladder Cancer
Via ACCESSWIRE

Performance

YTD
+24.00%
+24.00%
1 Month
-20.00%
-20.00%
3 Month
-38.00%
-38.00%
6 Month
-38.00%
-38.00%
1 Year
-36.67%
-36.67%

More News

Read More
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
Via ACCESSWIRE
Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
Via ACCESSWIRE
Exousia AI Ludwig Enterprises Subsidiary Launches Liposome Research Program
Via ACCESSWIRE
Ludwig Enterprises, Inc. Announces Marvin S. Hausman, M.D. as Chief Executive Officer
Via ACCESSWIRE
LUDG Files Genomic Patent AI Uncovers Differentially Expressed Genes
Via ACCESSWIRE
Ludwig Enterprises, Inc. (OTC: LUDG) Prepares to Trade on the OTCQB Market
Via ACCESSWIRE
Ludwig Enterprises Appoints Scott Silverman as CFO
Via ACCESSWIRE
Ludwig Enterprises Announces Effectiveness of Form S-1 Registration Application, Becomes an SEC Reporting Company
Via ACCESSWIRE
Ludwig Enterprises to Launch New Nutraceutical in Hair Loss Market
Via ACCESSWIRE
Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan
Via ACCESSWIRE
Ludwig Enterprises Launches NuGenea, Groundbreaking Nutraceutical to Fight Inflammation
Via ACCESSWIRE
Ludwig Enterprises Receives IRB Approval on Bladder Cancer Study
Via ACCESSWIRE
Ludwig Enterprises Releases Annual 2022 Shareholder Letter
Via ACCESSWIRE
Ludwig Enterprises Acquires Cutting-Edge Dietary Supplement Formula
Via ACCESSWIRE
Decoding mRNA for Early Disease Detection, Treatment & Prevention
Via ACCESSWIRE
Ludwig Enterprises Announces Agreement with Summit Bancorp to Assist with Cross Listing on the Canadian Stock Exchange
Via ACCESSWIRE
Ludwig Enterprises Announces Intention to List on the Canadian Stock Exchange
Via ACCESSWIRE
Ludwig Enterprises Developing New Partnerships to Fuel Growth
Via ACCESSWIRE
Ludwig Enterprise mRNA Program Generating Broad Clinical Interest
Via ACCESSWIRE
Ludwig Enterprises Announces Brand Name for Groundbreaking Nutraceutical
Via ACCESSWIRE
Ludwig Enterprises Develops Program to Support Ketamine Clinics
Via ACCESSWIRE
New Scientific Evidence Suggests How Chronic Illnesses May Be Prevented
Via ACCESSWIRE
Ludwig Enterprises Launches Growth Plan
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.